You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dillman RO, McClay E, Amatruda T, et al
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
Journal for ImmunoTherapy of Cancer 2015;3:P202. doi: 10.1186/2051-1426-3-S2-P202